Huiqiang Huang, MD, PhD, is a professor and deputy director of the Medical Oncology Department at Sun Yat-sen University Cancer Center in Guangzhou, China.

Dr Huang on the Efficacy of Sintilimab Plus Chidamide and P-GemOx in Treatment-Naive NKTL. 

"Based on these preliminary results, we can see that this treatment combination [produced] promising, durable responses for the treatment [of patients with] ENKTL."

Huiqiang Huang, MD, PhD, a professor and deputy director of the Medical Oncology Department at Sun Yat-sen University Cancer Center in Guangzhou, China, discussed key findings from the phase 2 SCENT-2 trial (NCT04994210), which evaluated sintilimab (Tyvyt) plus chidamide, followed by pegaspargase, gemcitabine, and oxaliplatin (P-GemOx) in patients with treatment-naive, early-stage extranodal natural killer/T-cell lymphoma (ENKTL).

 showed that patients treated with the combination in part A of the study (n = 47) 

achieved an objective response rate (ORR) of 80.8%

, of which 63.8% achieved complete response (CR); the partial response (PR), stable disease (SD), and progressive disease (PD) rates were 17.0%, 14.9%, and 4.3%, respectively, according to Huang. Following treatment with P-GemOx in part B, the ORR was 95.7%, with 93.6% achieving CR. The respective PR, SD, PD, and not evaluable (NE) rates were 2.1%, 0%, 0%, and 4.3%.

After patients were treated with involved-field radiotherapy in part C, the ORR was 95.7%, which were all CRs, and the remaining 4.3% were NE, Huang reported. At a median follow-up of 17.0 months (95% CI, 0.8-29.4), the 1-year progression-free survival rate was 95.7% (95% CI, 83.9%-98.9%), and the 1-year overall survival rate was 95.3% (95% CI, 82.2%-98.8%), he added.

Of note, Huang mentioned that 1 patient who achieved a CR died due to an intracranial hemorrhage from an accidental fall. Furthermore, the 1-year disease-free survival rate was 97.8% (95% CI, 85.3%-99.7%), and the 1-year duration of complete response rate was 97.8% (95% CI, 85.3%-99.7%), he explained.

Sintilimab/chidamide with P-GemOx might be a promising novel chemotherapy-reduced combination therapy with manageable toxicities for this population, and may be an effective induction regimen for treatment-naive patients with ENKTCL, Huang concluded.

Videos

Ajai Chari, MD, highlighted key areas of debate in smoldering myeloma from the Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma Conference.

Huiqiang Huang, MD, PhD

Articles

Dr Huang on the Efficacy of Sintilimab Plus Chidamide and P-GemOx in Treatment-Naive ENKTL.